This week, we discuss a promising step toward a functional cure for chronic hepatitis B, first-line pulsed field ablation for persistent atrial fibrillation, reducing the demand for transfusion in surgery, treatment for rifampicin-resistant tuberculosis, and a decade-long look at CAR T-cell therapy outcomes. We review peanut allergy and discuss a case of a man with leg weakness, pain, and weight loss; Perspectives explore GLP-1 access, air-quality policy, and the human realities of homelessness.
Fler avsnitt av NEJM This Week
Visa alla avsnitt av NEJM This WeekNEJM This Week med NEJM Group finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
